Chabiotech Co.,Ltd.

KOSDAQ 085660.KQ

Chabiotech Co.,Ltd. Free Cash Flow Yield on January 14, 2025: -11.29%

Chabiotech Co.,Ltd. Free Cash Flow Yield is -11.29% on January 14, 2025, a -78.34% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Chabiotech Co.,Ltd. 52-week high Free Cash Flow Yield is -5.81% on March 25, 2024, which is 48.57% above the current Free Cash Flow Yield.
  • Chabiotech Co.,Ltd. 52-week low Free Cash Flow Yield is -11.91% on December 23, 2024, which is -5.44% below the current Free Cash Flow Yield.
  • Chabiotech Co.,Ltd. average Free Cash Flow Yield for the last 52 weeks is -7.22%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
KOSDAQ: 085660.KQ

Chabiotech Co.,Ltd.

CEO Hoon Oh Sang
IPO Date Feb. 10, 2009
Location South Korea
Headquarters 442 Dosan-daero
Employees 271
Sector Health Care
Industries
Description

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease. Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email